Disease or Syndrome – Page 66

J&J’s Shockwave Medical Launches Novel Javelin Intravascular Lithotripsy Catheter for Treating Calcified Peripheral Artery Disease

8 months ago8 months ago talkbio0Tagged Calcified (qualifier), Intravascular, Lithotripsy, Medical Devices, Peripheral Arterial Diseases, Shockwave Medical, vascular intervention

Intravascular lithotripsy, peripheral artery disease, calcified lesions, Shockwave Medical, Johnson & Johnson, medical device, vascular intervention

Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care

8 months ago talkbio0Tagged Artificial Intelligence, Biosimilars, Clinical Trial Design, Combined, Immunotherapy for cancer, Neoplasms, Personalized cancer care, Precision Medicine, targeted therapies

Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care

FDA Pauses BioNTech’s Malaria Vaccine Trial Amid Regulatory Scrutiny

8 months ago talkbio0Tagged BioNTech, Malaria, regulatory, RNA Vaccine, Study on Hold, United States Food and Drug Administration, Vaccines

BioNTech, malaria vaccine, FDA clinical hold, RNA vaccine, regulatory challenges

Pliant Therapeutics Discontinues Phase 2b/3 Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis Due to Safety Concerns

8 months ago talkbio0Tagged BEACON-IPF, bexotegrast, Clinical Trials, concerns, Idiopathic Pulmonary Fibrosis, Pliant, Safety

Pliant Therapeutics, bexotegrast, BEACON-IPF trial, idiopathic pulmonary fibrosis (IPF), safety concerns, clinical trial discontinuation

AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog

8 months ago talkbio0Tagged AbbVie, Amylin Analog, GUB014295, GUBamy, Gubra, Obesity, pharmaceutical licensing, Weight-Loss Agents

AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal

The Perfect Storm: Why 2025 Will Be the Year of GxP AI in Pharma

8 months ago talkbio0Tagged Administration occupational activities, Artificial Intelligence, data-driven innovation, Drug Development, GxP, pharmaceutical manufacturing, Quality, regulatory

GxP AI, pharmaceutical manufacturing, regulatory compliance, data-driven innovation, quality management, drug development

Praxis Precision Medicines Faces Setback in Essential Tremor Drug Trial

8 months ago talkbio0Tagged Clinical Trials, Drops - Drug Form, Essential Tremor, Failure (biologic function), Praxis Precision Medicines, Prices

Praxis Precision Medicines, ulixacaltamide, essential tremor, clinical trial failure, stock price drop

Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge

9 months ago talkbio0Tagged Acquisition, Eli, Eli Lilly, FXR314, Increase, Inflammatory Bowel Diseases, NR1H4 gene, Organovo, Prices, Programs - Publication Format

Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase

Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

9 months ago talkbio0Tagged Comprehensive, Empowered, Epilepsy, Experience, Holistic epilepsy management, Interdisciplinary Studies, Patient-Centered, Quality of life

Patient-centered epilepsy care, Holistic epilepsy management, Quality of life in epilepsy, Empowering epilepsy patients, Multidisciplinary epilepsy treatment, Epilepsy patient experiences, Comprehensive epilepsy support